FUNCTION OF NOGGIN IN HAIR FOLLICLE GROWTH AND DISEASE
Project Number5K02AR048573-02
Contact PI/Project LeaderBOTCHKAREV, VLADIMIR A
Awardee OrganizationBOSTON UNIVERSITY MEDICAL CAMPUS
Description
Abstract Text
DESCRIPTION (provided by applicant): Despite different pathogenic
mechanisms, most common hair growth disorders (androgenic alopecia and alopecia
areata) are characterized by the development of hair follicle miniaturization
with significant elongation of the resting stage, shortening of the growth
stage of hair cycle, and hair loss. Molecular signals that trigger hair
follicle transformation from resting to active growth and from active growth to
the regression during postnatal development, in normal skin and in skin
affected by hair growth disorders are still poorly understood. Noggin is a
specific antagonist of bone morphogenic proteins 2 and 4 (BMP 2 and 4), members
of TGF beta BMP superfamily. Noggin binds Bmp 2 and 4 with high affinity and
prevents their interactions with BMP receptors. Noggin plays essential roles in
controlling morphogenesis of ectodermal derivatives (neural tube, feather, hair
follicle) and in regulating apoptosis during development. Noggin stimulates
morphogenesis of ectodermal derivatives and downregulates BMP mediated
apoptosis.
Hypothesis: Noggin plays important roles in the initiation of new hair growth
wave in postnatal skin and in the apoptosis driven hair follicle regression in
normal skin and in skin affected by alopecia areata.
Purpose: 1) Characterize expression of noggin, BMP 2 and 4, BMP receptors and
BMP target genes during hair cycle in C5713L6 mice and in C3HHeJ mice affected
by alopecia areata. 2) Define the roles for noggin and BMP 2 and 4 in hair
growth control by pharmacologically manipulating hair cycle in normal C57BL6
mice and in C3HHeJ mice affected by alopecia areata. 3) Determine the in vivo
function of noggin in the control of hair follicle growth by generating
noggin-overexpressing mice using versican or K5 as promoters. 4) Characterize
dynamics of alopecia areata development in C3HHeJ noggin transgenic mice
induced by grafting C3HHeJ mouse skin affected by alopecia areata. 5) Analyze
mechanisms of noggin and BMP 2 and 4 involvement in hair growth control by
analyzing alterations in expression of their target genes in the experimental
models mentioned above.
Investigation of the in vivo functions of noggin and BMP 2 and 4 as putative
modulators of hair follicle cycling in normal skin and in skin affected by
alopecia areata is intended to provide new knowledge into hair cycle biology
and could raise a possibility to explore BMP antagonists for the treatment of
this disorder.
National Institute of Arthritis and Musculoskeletal and Skin Diseases
CFDA Code
846
DUNS Number
604483045
UEI
FBYMGMHW4X95
Project Start Date
01-June-2002
Project End Date
31-May-2007
Budget Start Date
01-June-2003
Budget End Date
31-May-2004
Project Funding Information for 2003
Total Funding
$97,686
Direct Costs
$90,450
Indirect Costs
$7,236
Year
Funding IC
FY Total Cost by IC
2003
National Institute of Arthritis and Musculoskeletal and Skin Diseases
$97,686
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5K02AR048573-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5K02AR048573-02
Patents
No Patents information available for 5K02AR048573-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5K02AR048573-02
Clinical Studies
No Clinical Studies information available for 5K02AR048573-02
News and More
Related News Releases
No news release information available for 5K02AR048573-02
History
No Historical information available for 5K02AR048573-02
Similar Projects
No Similar Projects information available for 5K02AR048573-02